Clinical Trials Logo

Meningioma clinical trials

View clinical trials related to Meningioma.

Filter by:

NCT ID: NCT00019578 Completed - Brain Metastases Clinical Trials

Stereotactic Radiosurgery in Treating Patients With Brain Tumors

Start date: November 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.

NCT ID: NCT00010049 Completed - Clinical trials for Brain and Central Nervous System Tumors

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Start date: February 27, 2001
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for recurrent glioma and meningioma. PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate in treating patients who have progressive, recurrent, or unresectable malignant glioma or meningioma.

NCT ID: NCT00006119 Completed - Clinical trials for Brain and Central Nervous System Tumors

Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

Start date: July 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

NCT ID: NCT00004483 Active, not recruiting - Meningioma Clinical Trials

NF2 Natural History Consortium

Start date: January 2002
Phase: N/A
Study type: Observational

OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.

NCT ID: NCT00004078 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Irinotecan in Treating Children With Refractory Solid Tumors

Start date: October 1999
Phase: Phase 2
Study type: Interventional

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00003590 Completed - Adult Meningioma Clinical Trials

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Start date: November 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.

NCT ID: NCT00003483 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Antineoplaston Therapy in Treating Patients With Meningioma

Start date: August 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating patients who have meningioma that has progressed or recurred after surgery and radiation therapy.

NCT ID: NCT00003292 Terminated - Chondrosarcoma Clinical Trials

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Start date: July 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.

NCT ID: NCT00002965 Completed - Clinical trials for Brain and Central Nervous System Tumors

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Start date: January 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresectable meningiomas and malignant meningiomas.